

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Imaging			
Fluorescently labeled anti-CD47 antibody for bladder cancer diagnosis	<p>Fluorescently tagged anti-CD47 antibodies could help diagnose bladder cancer. In <i>ex vivo</i> intact human bladders, blue light cystoscopy using a labeled anti-CD47 antibody that targets receptors on the surface of bladder cancer cells enabled identification of malignant lesions with 82.9% sensitivity and 90.5% specificity. Blue light cystoscopy with the imaging agent also identified difficult-to-diagnose bladder cancer variants including flat carcinomas and recurrent bladder cancer in patients following bacillus Calmette-Guérin (BCG) therapy or surgical resection. Next steps include assessing the toxicity of the labeled antibody in humans.</p> <p>Radiation Control Technologies Inc. has RCT1938, a selective radiosensitizer that inhibits CD47, in preclinical development for cancer.</p> <p>SciBX 7(45); doi:10.1038/scibx.2014.1334 Published online Nov. 20, 2014</p>	Patent applications filed; unavailable for licensing	<p>Pan, Y. <i>et al. Sci. Transl. Med.</i>; published online Oct. 29, 2014; doi:10.1126/scitranslmed.3009457</p> <p>Contact: Joseph C. Liao, Stanford University, Stanford, Calif. e-mail: jliao@stanford.edu</p>